Circovirus sequences associated with piglet weight loss disease (PWD)

• US 7,951,907 B2
• Filed: 11/13/2009
• Issued: 05/31/2011
• Est. Priority Date: 12/05/1997
• Status: Expired due to Fees

• Current Assignee: Zoetis Services LLC (Zoetis Incorporated)
• Original Assignee: Wyeth LLC (Pfizer Inc.)
• Inventors: Hutet, Evelyne, Blanchard, Philippe, Le Cann, Pierre, Albina, Emmanuel, Cariolet, Roland, Mahe, Dominique, Arnauld, Claire, Truong, Catherine, Jestin, André, Madec, François
• Primary Examiner(s): Salimi; Ali R.
• Application Number:
  US12/618,485
• Publication Number:
  US 20100221283A1
• Time in Patent Office: 564 Days
• Field of Search: None
• US Class Current: 530/300
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/58 raising an immune response against a target which is not the antigen used for immunisation
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: C07K 14/005 : from viruses
• CPC Class Codes: C07K 2319/55 : containing a fusion with a toxin, e.g. diphteria toxin
• CPC Class Codes: C12N 2710/14143 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/10021 : Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2750/10022 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/10034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2750/10051 : Methods of production or purification of viral material
• CPC Class Codes: C12N 2750/10061 : Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: G01N 2333/01 : DNA viruses
• CPC Class Codes: G01N 2469/20 : Detection of antibodies in sample from host which are directed against antigens from microorganisms
• CPC Class Codes: G01N 33/56983 : Viruses
• CPC Class Codes: Y10T 428/13 : Hollow or container type article [e.g., tube, vase, etc.]

Abstract

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Claims

1. A vaccine comprising:

a pharmaceutically or veterinarily acceptable carrier; and

an isolated immunogenic porcine circovirus Type B (PCVB) polypeptide having at least 90% identity to the sequence of SEQ ID NO;

26, wherein the polypeptide induces an immunological response in a porcine against PCVB.

2. The vaccine according to claim 1, wherein the isolated immunogenic porcine circovirus Type B (PCVB) polypeptide has at least 95% identity to the sequence of SEQ ID NO:

26.

3. The vaccine according to claim 1, wherein the immunogenic PCVB polypeptide has at least 98% identity to SEQ ID NO:

26.

4. The vaccine according to claim 1, wherein the immunogenic PCVB polypeptide has the sequence of SEQ ID NO:

26.

5. The vaccine according to any one of claims 1-4, wherein the polypeptide is generated by recombinant production.

6. The vaccine according to any one of claims 1-4, wherein the polypeptide is generated by chemical synthesis.

7. The vaccine according to any one of claims 1-6, further comprising an adjuvant.